What can be done to make vaccines more trendy?

Expert Review of Vaccines

Volumn 4, Issue 1, 2005, Pages 23-25

  Andre, Francis E ^a,b  

^a GSK Biologicals ^*  (Belgium)

^b GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

Author keywords

Research and development; Society; Vaccines

Indexed keywords

LYME DISEASE VACCINE; ROTAVIRUS VACCINE; VACCINE;

CAREER; COST EFFECTIVENESS ANALYSIS; DEVELOPING COUNTRY; DRUG COST; DRUG INDUSTRY; DRUG MARKETING; FINANCIAL MANAGEMENT; HEALTH CARE COST; HEALTH CARE ORGANIZATION; HEALTH PROMOTION; HUMAN; INTESTINE INTUSSUSCEPTION; MASS MEDIUM; MEDICAL PRACTICE; PRIORITY JOURNAL; PROFESSIONAL PRACTICE; REVIEW; VACCINATION;

ATTITUDE TO HEALTH; DRUG DESIGN; HUMANS; MARKETING OF HEALTH SERVICES; PHYSICIAN'S PRACTICE PATTERNS; PUBLIC OPINION; VACCINATION; VACCINES;

EID: 14744278732     PISSN: 14760584     EISSN: None     Source Type: Journal    
DOI: 10.1586/14760584.4.1.23     Document Type: Review

References (7)

1. André FE. Vaccinology: past achievements, present roadblocks and future promises. Vaccine 21, 593-595 (2003).
2. Jefferson T. Vaccination and its adverse effects: real or perceived? Br. Med. J. 317, 159-160 (1998).
3. Ehreth J. The global value of vaccination. Vaccine 21, 596-600 (2003).
4. Berman S, Giffin RB. Global perspective on vaccine financing. Expert. Rev. Vaccines 3, 557-562 (2004).
5. André FE. How the research-based industry approaches vaccine development and establishes priorities. Dev. Biol. Basel 110, 25-29 (2002).
6. Kaddar M, Lydon P, Levine R. Financial challenges of immunization: a look at GAVI. Bull. World Health Org. 82, 697-702 (2004).
7. Poland GA, Jacobson RM. Understanding those who don't understand: a brief review of the antivaccine movement. Vaccine 19, 2440-2445 (2001).